Ghent, Belgium, March 31, 2022 (GLOBE NEWSWIRE) -- Press release
Biotalys (Euronext: BTLS), an Agricultural Technology (AgTech) company protecting crops and food with protein-based biocontrol solutions, is pleased to announce the appointment of Dr. Carlo Boutton as Chief Scientific Officer (CSO), effective 3 May 2022.
“I’m delighted to welcome Carlo as a new member of the Executive Committee of Biotalys,” said Simon Moroney, Chairman of Biotalys. “With a wealth of experience working with antibody innovation and an exemplary track record building world-class research platforms, he is an outstanding addition to the team.”
“The proteins we use in our products are inspired by naturally occurring antibodies, aiming to protect food from the field to the plate,” commented Patrice Sellès, CEO of Biotalys. “As we continue to develop our technology platform, Carlo will support the acceleration of technical innovation in the next stage of Biotalys’ growth, ensuring we can offer growers safe, effective and sustainable alternatives to conventional crop protection products.”
Most recently serving as the Global Head of Innovation for Large Molecules Research at global healthcare and pharmaceutical leader Sanofi, Dr. Boutton brings more than 20 years of antibody and biochemistry leadership to his new executive role at Biotalys. Reporting to Biotalys’ CEO Patrice Sellès, Dr. Boutton will lead the team’s continued scientific research to further develop the novel AGROBODY Foundry™ technology platform, preparing Biotalys’ pipeline of biofungicides, biobactericides and bio-insecticides for expansion and commercial availability while building its intellectual property portfolio.
“Biotalys is at the forefront of innovation in agricultural technology. I could not pass up the opportunity to join Biotalys and apply proven science to address such an important global issue – the safe and sustainable production of our food,” noted Dr. Boutton. “Antibody-inspired proteins have the potential to bring completely new compounds and modes of action to farms around the world so we can better protect our crops, consumers and ecosystem. I look forward to working with the exceptionally talented Biotalys team to continue its innovation in AGROBODY™ biocontrols.”
In his most recent role as Sanofi’s Global Head of Innovation, Large Molecules Research, Dr. Boutton drove the innovation strategy and managed an expansive team exploring novel technologies with antibodies, NANOBODIES® and other biologic modalities to find innovative pharmaceutical solutions. Before Sanofi, Dr. Boutton held various scientific leadership roles at Ablynx (now Sanofi), where he focused on bioinformatics, protein modelling and finding new therapeutic applications for its NANOBODY® platform. At Ablynx, he was also involved in multiple strategic partnerships as member of Joint Steering Committees. Previously, he took part in several anti-HIV and anti-HCV drug discovery projects at Tibotec (a subsidiary of Johnson & Johnson). At the start of his career, he contributed to the development of a platform to develop rationally designed therapeutics in the broad field of immunotherapy, at Algonomics (now Lonza). He is named co-inventor on more than 20 patent applications.
Carlo Boutton obtained his M.S. and PhD from the University of Leuven (Belgium), where he researched the physico-chemical behavior of proteins under high-electromagnetic fields.
About Biotalys
Biotalys is an Agricultural Technology (AgTech) company protecting crops and food with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply. Based on its novel AGROBODY™ technology platform, Biotalys is developing a strong and diverse pipeline of effective product candidates with a favorable safety profile that aim to address key crop pests and diseases across the whole value chain, from soil to plate. Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is listed on Euronext Brussels since July 2021. The company is based in the biotech cluster in Ghent, Belgium. More information can be found on www.biotalys.com.
For further information, please contact
Toon Musschoot, Head of IR & Communication
T: +32 (0)9 274 54 00
E: Toon.Musschoot@biotalys.com
Important Notice
This announcement contains statements which are "forward-looking statements" or could be considered as such. These forward-looking statements can be identified by the use of forward-looking terminology, including the words ‘aim’, 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are warned that none of these forward-looking statements offers any guarantee of future performance. The Biotalys actual results may differ materially from those predicted by the forward-looking statements. Biotalys makes no undertaking whatsoever to publish updates or adjustments to these forward-looking statements, unless required to do so by law.
